ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Improvement in Bone Properties by Using Risedronate Adsorbed Hydroxyapatite Novel Nanoparticle Based Formulation in a Rat Model of Osteoporosis

Sahana, H and Khajuria, Deepak Kumar and Razdan, Rema and Mahapatra, Roy D and Bhat, MR and Suresh, Sarasija and Rao, Ramachandra R and Mariappan, L (2013) Improvement in Bone Properties by Using Risedronate Adsorbed Hydroxyapatite Novel Nanoparticle Based Formulation in a Rat Model of Osteoporosis. In: JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 9 (2). pp. 193-201.

Full text not available from this repository. (Request a copy)
Official URL: http://dx.doi.org/10.1166/jbn.2013.1482


A superior drug formulation capable of achieving efficient osteogenesis is in imperative demand for the treatment of osteoporosis. In the present study we investigated the potential of using novel risedronate-hydroxyapatite (HA) nanoparticle based formulation in an animal model of established osteoporosis. Nanoparticles of HA loaded with risedronate (NHLR) of various sizes (80-130 nm) were generated for bone targeted drug delivery. Three months after ovariectomy, 36 ovariectomized (OVX) rats were divided into 6 equal groups and treated with various doses of NHLR (500,350 and 250 mu g/kg intravenous single dose) and sodium risedronate (500 mu g/kg, intravenous single dose). Untreated OVX and sham OVX served as controls. One month after drug administration, the left tibia and femur were tested for bone mechanical properties and histology, respectively. In the right femur, bone density was measured by method based on Archimedes principle and bone porosity analyses were performed using X-ray imaging. NHLR (250 mu g/kg) showed a significant increase in bone density and reduced bone porosity when compared with OVX control. Moreover, NHLR (250 mu g/kg) significantly increased bone mechanical properties and bone quality when compared with OVX control. The results strongly suggest that the NHLR, which is a novel nanoparticle based formulation, has a therapeutic advantage over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model of postmenopausal osteoporosis.

Item Type: Journal Article
Additional Information: Copyright for this article belongs to AMER SCIENTIFIC PUBLISHERS, VALENCIA,USA
Keywords: Rat; Ovariectomy;Osteoporosis;Risedronate;Hydroxyapatite Nanoparticles;Biomechanical Properties;Bone Density;Bone Porosity
Department/Centre: Division of Mechanical Sciences > Aerospace Engineering(Formerly Aeronautical Engineering)
Date Deposited: 06 Mar 2013 11:04
Last Modified: 06 Mar 2013 11:04
URI: http://eprints.iisc.ac.in/id/eprint/45945

Actions (login required)

View Item View Item